This study is looking for healthy adults aged 18-65 to understand how their bodies process the malaria prevention drug, Tafenoquine (ARAKODA). Researchers want to see how different genetic makeups affect how Tafenoquine is changed into its active form in the body. You would receive a single 300mg dose of Tafenoquine. The main goal is to measure the levels of Tafenoquine in your blood and urine over about two months to understand how your body handles the drug. This information helps us learn more about how Tafenoquine works in different people.

Study design

This is an interventional study planning to enroll 20 healthy adult participants. It will examine how different genetic types (CYP450 2D6 phenotypes) process Tafenoquine.

What's involved

You would take a single dose of Tafenoquine and have blood and urine samples collected at specific times over approximately two months. You would also need to use contraception and avoid certain over-the-counter antioxidants for a period.

Compensation

Not stated in the trial record.

Follow-up

Blood and urine levels of Tafenoquine will be measured for up to 57 days after the dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.